Piper Sandler Reiterates Overweight Rating on Masimo Corp. (MASI)

Piper Sandler analyst Jason Bednar reiterated an Overweight rating and $165.00 price target on Masimo Corp. (NASDAQ: MASI).

The analyst commented, "We are hosting another installment of our Bull vs. Bear debate series within the MedTech group at Piper Sandler with MASI the focus of today's debate. Shares are up 30% over the past month since the shareholder vote and subsequent developments (management and Board updates, commitment to a strategic review of Consumer, reaffirming 3Q guidance), but we see that move as just the beginning. Not only do we see a further move higher as additional components of the MASI investment case are de-risked, but we also expect an earnings power inflection in 25/26 as greater for this stock than any other in our coverage universe (and Street estimates don't at all reflect this upside yet). Plus, there's an intriguing call option that could develop with upcoming Apple litigation. We'll discuss these topics in greater detail on today's call, and we're now elevating MASI to top idea status on our list."

For an analyst ratings summary and ratings history on Masimo Corp. click here. For more ratings news on Masimo Corp. click here.

Shares of Masimo Corp. closed at $142.95 yesterday.

You May Also Be Interested In

• JD.com (JD) Reiterated at Buy by Benchmark Amid Earnings Recovery
• Cantor Fitzgerald Reiterates Overweight Rating on Merlin Labs (MRLN)
• Pro Diversity Network (IPDN) Reports Q2 Loss of $0.15